LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Avatud

SektorTervishoid

2.48 1.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.4

Max

2.51

Põhinäitajad
By Trading Economics
Sissetulek	-27M -17M
Müük	586K 718K
Aktsiakasum	-0.125
Kasumimarginaal	-2,366.017
Töötajad	23
EBITDA	-5.5M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+118.44% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 458M
Eelmine avamishind	0.84
Eelmine sulgemishind	2.48

Uudiste sentiment

By Acuity

50%

148 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21. mai 2026, 16:49 UTC

Tulu

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21. mai 2026, 16:26 UTC

Suurimad hinnamuutused turgudel

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21. mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21. mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21. mai 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164M

21. mai 2026, 21:53 UTC

Tulu

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21. mai 2026, 21:02 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21. mai 2026, 20:55 UTC

Tulu

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21. mai 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21. mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Adj EPS 3c >BULL

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Rev $159.9M >BULL

21. mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21. mai 2026, 20:18 UTC

Tulu

Webull 1Q Loss/Shr 4c

21. mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21. mai 2026, 18:58 UTC

Tulu

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21. mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21. mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21. mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21. mai 2026, 17:01 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21. mai 2026, 16:20 UTC

Market Talk

Tulu

Stellantis Targets Distant but Constructive -- Market Talk

21. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

118.44% tõus

12 kuu keskmine prognoos

Keskmine 5.33 USD 118.44%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

148 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.